Novel sulfamides and their use as endothelin receptor antagonists
CA 2431675 C · Owner: Actelion Pharmaceuticals Ltd. · Inventors: Weller, Thomas; Clozel, Martine; Boss, Christoph
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to novel sulfamides of general formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 4, 2001 and granted November 8, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 4, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 4, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.